查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1618135

肿瘤精准医学市场机会、成长动力、产业趋势分析与预测 2024 - 2032

Oncology Precision Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 138 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球肿瘤精准医疗市场规模达到417亿美元，预计2024年至2032年复合年增长率为9.1%。随着癌症诊断数量的增加，对特定基因突变的个人化治疗方案的需求不断增加，最终提高治疗效果。这一趋势凸显了精准肿瘤治疗的必要性，这种治疗能够提供有针对性的、有效的治疗，且副作用最小，从而改善患者的生活品质。此外，由于对癌症基因组学的更深入了解以及下一代定序（NGS）和液体活检等尖端技术的引入，市场正在迅速发展。

这些创新有助于识别特定的基因突变和生物标记物，帮助肿瘤学家为个别患者选择最合适的标靶疗法或免疫疗法。就癌症类型而言，市场涵盖多种类别，包括乳癌、肺癌、血液癌、胃肠道癌、皮肤癌等。 2023 年，乳癌细分市场以 22.3% 的份额引领市场，因为精准医疗专注于与此类癌症相关的特定基因突变的标靶治疗。透过强调分子分析和客製化治疗计划，该细分市场在市场上获得了巨大的吸引力。

在考虑给药途径时，肿瘤精准医疗市场分为口服、静脉注射和其他给药方式。 2023 年，仅口腔领域的价值就达到 268 亿美元，预计在预测期内复合年增长率为 10.2%。这种增长可归因于人们越来越倾向于口服药物，与静脉注射药物相比，口服药物提供了更大的便利性。精准医学中标靶治疗的兴起也推动了口服药物领域的发展，因为包括激酶抑制剂在内的许多肿瘤药物都被製成口服药物。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 417 亿美元
预测值 907 亿美元
复合年增长率 9.1%

这使得能够根据个体肿瘤的独特基因组成更精确地靶向癌细胞。北美肿瘤精准医疗市场将于 2023 年达到 213 亿美元，预计 2024 年至 2032 年复合年增长率为 10.2%。研究与开发。公部门和私部门对癌症研究的投资刺激了创新，而监管机构则加快了精准治疗的审批流程。医疗保健提供者和患者对个人化医疗的认识不断提高，进一步提高了采用率，推动了市场扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 癌症盛行率上升
      • 提高认识并转向个人化治疗
      • 技术进步
    • 产业陷阱与挑战
      • 精准医疗成本高
      • 复杂的监管审批流程
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按癌症类型，2021 - 2032 年

  • 主要趋势
  • 乳癌
  • 肺癌
  • 血液/血液癌症
  • 胃肠癌
  • 皮肤癌
  • 膀胱癌
  • 头颈鳞状细胞癌
  • 子宫颈癌
  • 其他癌症类型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 口服
  • 静脉
  • 其他给药途径

第 7 章：市场估计与预测：按分子类型，2021 - 2032

  • 主要趋势
  • 小分子
  • 生物製剂

第 8 章：市场估计与预测：按药物类别，2021 - 2032 年

  • 主要趋势
  • 激酶抑制剂
  • 免疫检查点抑制剂
  • 酵素抑制剂
  • 其他药物类别

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • AbbVie
  • AstraZeneca
  • Bayer
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Organon
  • Pfizer
简介目录
Product Code: 11876

The Global Oncology Precision Medicine Market reached USD 41.7 billion in 2023 and is projected to expand at a CAGR of 9.1% from 2024 to 2032. A key factor driving the growth of this market is the rising incidence of cancer. With an increasing number of cancer diagnoses, there is a heightened demand for personalized treatment options that target specific genetic mutations, ultimately enhancing treatment outcomes. This trend highlights the necessity for precision oncology therapies that provide targeted, effective treatments with minimal side effects, thus improving patients' quality of life. Moreover, the market is rapidly advancing due to a greater understanding of cancer genomics and the introduction of cutting-edge technologies like next-generation sequencing (NGS) and liquid biopsy.

These innovations facilitate the identification of specific genetic mutations and biomarkers, helping oncologists select the most suitable targeted therapies or immunotherapies for individual patients. In terms of cancer types, the market encompasses various categories, including breast cancer, lung cancer, hematologic cancers, gastrointestinal cancers, skin cancer, and several others. The breast cancer segment led the market with a 22.3% share in 2023, as precision medicine focuses on targeted therapies addressing specific genetic mutations associated with this type of cancer. By emphasizing molecular profiling and customized treatment plans, this segment has gained significant traction in the market.

When considering routes of administration, the oncology precision medicine market is divided into oral, intravenous, and other delivery methods. The oral segment alone was valued at USD 26.8 billion in 2023 and is expected to grow at a CAGR of 10.2% during the forecast period. This growth can be attributed to the growing inclination for oral medicines, which offer greater convenience compared to intravenous options. The rise of targeted therapies in precision medicine has also bolstered the oral segment, as many oncology drugs, including kinase inhibitors, are formulated as oral medications.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$41.7 Billion
Forecast Value$90.7 Billion
CAGR9.1%

This allows for more precise targeting of cancer cells based on the unique genetic makeup of individual tumors. North America oncology precision medicine market reached USD 21.3 billion in 2023 and is forecasted to grow at a CAGR of 10.2% from 2024 to 2032. The growth in this region is primarily fueled by a high prevalence of cancer and a robust healthcare infrastructure that supports innovative research and development. Investments from both the public and private sectors in cancer research stimulate innovation, while regulatory bodies expedite the approval process for precision therapies. Increased awareness of personalized medicine among healthcare providers and patients further enhances adoption rates, driving market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer
      • 3.2.1.2 Increasing awareness and shift towards personalized therapies
      • 3.2.1.3 Technological advancements
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of precision medicine
      • 3.2.2.2 Complex regulatory approval process
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Breast cancer
  • 5.3 Lung cancer
  • 5.4 Blood/ hematologic cancer
  • 5.5 Gastrointestinal cancer
  • 5.6 Skin cancer
  • 5.7 Bladder cancer
  • 5.8 Head & neck squamous cell cancer
  • 5.9 Cervical cancer
  • 5.10 Other cancer types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Intravenous
  • 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Molecule Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Small molecules
  • 7.3 Biologics

Chapter 8 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Kinase inhibitors
  • 8.3 Immune checkpoints inhibitors
  • 8.4 Enzyme inhibitors
  • 8.5 Other drug classes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 AbbVie
  • 10.2 AstraZeneca
  • 10.3 Bayer
  • 10.4 Blueprint Medicines Corporation
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Eli Lilly and Company
  • 10.7 F. Hoffmann-La Roche
  • 10.8 GlaxoSmithKline
  • 10.9 Merck
  • 10.10 Novartis
  • 10.11 Organon
  • 10.12 Pfizer